# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT3860357

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
ANTONIN DEFOUGEROLLES	05/06/2011
TATIANA NOVOBRANTSEVA	05/06/2011
BRIAN BETTENCOURT	05/10/2011

## **RECEIVING PARTY DATA**

Name:	ALNYLAM PHARMACEUTICALS
Street Address:	300 THIRD STREET
Internal Address:	THIRD FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	13938349

## **CORRESPONDENCE DATA**

Fax Number: (617)345-1300

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6173451000

Email: jsanchez@nixonpeabody.com, bostonpatent@nixonpeabody.com

**NIXON PEABODY Correspondent Name:** Address Line 1: 100 SUMMER STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	051058-069100-C
NAME OF SUBMITTER:	MARK J. FITZGERALD
SIGNATURE:	/Mark J. FitzGerald/
DATE SIGNED:	05/02/2016

**Total Attachments: 2** 

source=2016-05-02 SignedAssign 051058 069100 US#page1.tif source=2016-05-02 SignedAssign 051058 069100 US#page2.tif

**PATENT** REEL: 038477 FRAME: 0521 503813709

Attorney Docket No.: 051058-069000-US U.S. Serial No.: 13/081,270

#### ASSIGNMENT

WHEREAS, WE, Antonin DeFougerolles, a citizen of Canada, with an address of c/o Alnylam Pharmaceuticals, Inc., 300 Third Street, Third Floor, Cambridge, MA 02142; Tatiana Novobrantseva, a United States citizen, with an address of c/o Alnylam Pharmaceuticals, Inc., 300 Third Street, Third Floor, Cambridge, MA 02142; and Brian Bettencourt, a United States citizen, with an address of c/o Alnylam Pharmaceuticals, Inc., 300 Third Street, Third Floor, Cambridge, MA 02142; have invented certain new and useful improvements in COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE, for which we have executed an application for Letters Patent in the United States, which can be found in United States Patent Application No. 13/081,270 filed on April 6, 2011, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional No. 61/321,263 filed on April 6, 2010; and naming us as inventors;

AND WHEREAS, Alnylam Pharmaceuticals, Inc., with its principal place of business at 300 Third Street, Third Floor, Cambridge, MA 02142; desires to acquire the entire right, title and interest in and to the said improvements and the said Application:

NOW, THEREFORE, for good and valuable consideration, including salary or payment for the making of inventions, or employee benefits, the receipt of which is hereby acknowledged, we, the said inventors, do hereby acknowledge that we have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said Alnylam Pharmaceuticals, Inc., its successors, legal representatives and assigns, the entire right, title and interest throughout the world in, to and under the said improvements, and the said application and all divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, and all Letters Patent which may be granted for said improvements in any country or countries foreign to the United States and all extensions, renewals and reissues thereof; and we hereby authorize and request the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue Patents on applications as aforesaid, to issue all Letters Patent for said improvements to the said Alnylam Pharmaceuticals, Inc., its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant and agree that we will communicate to the said Alnylam Pharmaceuticals, Inc., its successors, legal representatives and assigns, any facts known to us respecting said improvements and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said Alnylam Pharmaceuticals, Inc., its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said improvements in all countries.

Attorney Docket No.: 051058-069000-US U.S. Serial No.: 13/081,270

The undersigned hereby grant(s) the law firm of Nixon Peabody LLP of 100 Summer Street, Boston, Massachusetts 02110-2131, U.S.A. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, I, Antonin DeFougerolles, he	reunto set my signature this
day of May, 2011.  Antonin DeFouge	2 Tee Clu
IN TESTIMONY WHEREOF, I, Tatiana Novobrantseva, he day of	
IN TESTIMONY WHEREOF, I, Brian Bettencourt, hercunt day of, 2011.	et (S

ALN-116

**RECORDED: 05/05/2016** 

**REEL: 038477 FRAME: 0523**